Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Dostarlimab - GSK

Next Previous
X
Search
Drug Profile

Dostarlimab - GSK

Alternative Names: ANB 011; Dostarlimab-gxly; GSK-4057190; GSK-4057190A; JEMPERLI; Jemperli; TSR 042; WBP 285

Latest Information Update: 28 Aug 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator AnaptysBio
  • Developer GSK; Italian Sarcoma Group
  • Class Antineoplastics; Immunotherapies; Monoclonal antibodies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; Programmed cell death 1 receptor antagonists; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Endometrial cancer; Solid tumours
  • Phase III Colorectal cancer; Fallopian tube cancer; Ovarian cancer; Peritoneal cancer; Squamous cell cancer
  • Phase II/III Non-small cell lung cancer
  • Phase II Breast cancer; Cervical cancer; Clear cell sarcoma; Liver cancer; Malignant melanoma; Neuroendocrine tumours; Pancreatic cancer; Rectal cancer; Small cell lung cancer

Most Recent Events

  • 23 Aug 2024 GlaxoSmithKline plans a phase II AZUR-4 trial for Adenocarcinoma (Neoadjuvant therapy, Late-stage disease, First line therapy, Combination therapy) in Belgium, Spain and United Kingdom in December 2024 (Parenteral) (NCT06567782)
  • 02 Aug 2024 US FDA approves sNDA application for dostarlimab in Endometrial cancer (Combination therapy, First-line therapy, Late-stage disease, Recurrent)
  • 02 Aug 2024 Efficacy and adverse events data from part 1 of phase III RUBY trial in Endometrial cancer released by GSK

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top